vs
Embecta Corp.（EMBC）与Essex Property Trust（ESS）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是Embecta Corp.的1.8倍（$479.6M vs $261.2M），Essex Property Trust净利率更高（17.9% vs 16.9%，领先1.0%），Essex Property Trust同比增速更快（5.5% vs -0.3%），过去两年Essex Property Trust的营收复合增速更高（6.0% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
EMBC vs ESS — 直观对比
营收规模更大
ESS
是对方的1.8倍
$261.2M
营收增速更快
ESS
高出5.8%
-0.3%
净利率更高
ESS
高出1.0%
16.9%
两年增速更快
ESS
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $479.6M |
| 净利润 | $44.1M | $85.7M |
| 毛利率 | 61.9% | 70.0% |
| 营业利润率 | 31.9% | 31.7% |
| 净利率 | 16.9% | 17.9% |
| 营收同比 | -0.3% | 5.5% |
| 净利润同比 | — | -71.6% |
| 每股收益（稀释后） | $0.74 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCESS
| Q4 25 | $261.2M | $479.6M | ||
| Q3 25 | $264.0M | $473.3M | ||
| Q2 25 | $295.5M | $469.8M | ||
| Q1 25 | $259.0M | $464.6M | ||
| Q4 24 | $261.9M | $454.5M | ||
| Q3 24 | $286.1M | $450.7M | ||
| Q2 24 | $272.5M | $442.4M | ||
| Q1 24 | $287.2M | $426.9M |
净利润EMBCESS
| Q4 25 | $44.1M | $85.7M | ||
| Q3 25 | $26.4M | $172.7M | ||
| Q2 25 | $45.5M | $231.5M | ||
| Q1 25 | $23.5M | $212.8M | ||
| Q4 24 | $0 | $301.7M | ||
| Q3 24 | $14.6M | $125.5M | ||
| Q2 24 | $14.7M | $99.0M | ||
| Q1 24 | $28.9M | $285.1M |
毛利率EMBCESS
| Q4 25 | 61.9% | 70.0% | ||
| Q3 25 | 60.0% | 69.2% | ||
| Q2 25 | 66.7% | 70.7% | ||
| Q1 25 | 63.4% | 69.6% | ||
| Q4 24 | 60.0% | 70.0% | ||
| Q3 24 | 60.7% | 69.5% | ||
| Q2 24 | 69.8% | 70.8% | ||
| Q1 24 | 64.6% | 69.7% |
营业利润率EMBCESS
| Q4 25 | 31.9% | 31.7% | ||
| Q3 25 | 21.4% | 44.5% | ||
| Q2 25 | 31.8% | 59.5% | ||
| Q1 25 | 24.3% | 55.3% | ||
| Q4 24 | 11.0% | 67.0% | ||
| Q3 24 | 9.2% | 28.6% | ||
| Q2 24 | 20.5% | 31.1% | ||
| Q1 24 | 13.6% | 31.0% |
净利率EMBCESS
| Q4 25 | 16.9% | 17.9% | ||
| Q3 25 | 10.0% | 36.5% | ||
| Q2 25 | 15.4% | 49.3% | ||
| Q1 25 | 9.1% | 45.8% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | 5.1% | 27.8% | ||
| Q2 24 | 5.4% | 22.4% | ||
| Q1 24 | 10.1% | 66.8% |
每股收益（稀释后）EMBCESS
| Q4 25 | $0.74 | $1.24 | ||
| Q3 25 | $0.44 | $2.56 | ||
| Q2 25 | $0.78 | $3.44 | ||
| Q1 25 | $0.40 | $3.16 | ||
| Q4 24 | $0.00 | $4.00 | ||
| Q3 24 | $0.24 | $1.84 | ||
| Q2 24 | $0.25 | $1.45 | ||
| Q1 24 | $0.50 | $4.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $76.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $5.5B |
| 总资产 | $1.1B | $13.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCESS
| Q4 25 | $201.3M | $76.2M | ||
| Q3 25 | $225.5M | $66.0M | ||
| Q2 25 | $230.6M | $58.7M | ||
| Q1 25 | $209.3M | $98.7M | ||
| Q4 24 | $210.0M | $66.8M | ||
| Q3 24 | $267.5M | $71.3M | ||
| Q2 24 | $275.1M | $55.2M | ||
| Q1 24 | $299.8M | $499.0M |
总债务EMBCESS
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | $6.4B | ||
| Q2 24 | — | $6.2B | ||
| Q1 24 | — | $6.6B |
股东权益EMBCESS
| Q4 25 | $-613.1M | $5.5B | ||
| Q3 25 | $-650.6M | $5.6B | ||
| Q2 25 | $-669.6M | $5.6B | ||
| Q1 25 | $-736.2M | $5.6B | ||
| Q4 24 | $-768.8M | $5.5B | ||
| Q3 24 | $-738.3M | $5.4B | ||
| Q2 24 | $-763.7M | $5.5B | ||
| Q1 24 | $-769.6M | $5.5B |
总资产EMBCESS
| Q4 25 | $1.1B | $13.2B | ||
| Q3 25 | $1.1B | $13.2B | ||
| Q2 25 | $1.2B | $13.2B | ||
| Q1 25 | $1.1B | $13.2B | ||
| Q4 24 | $1.1B | $12.9B | ||
| Q3 24 | $1.3B | $12.6B | ||
| Q2 24 | $1.3B | $12.5B | ||
| Q1 24 | $1.2B | $12.9B |
负债/权益比EMBCESS
| Q4 25 | — | — | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 1.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $1.1B |
| 自由现金流经营现金流 - 资本支出 | $16.6M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 0.39× | 12.53× |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCESS
| Q4 25 | $17.2M | $1.1B | ||
| Q3 25 | $84.0M | $342.6M | ||
| Q2 25 | $81.2M | $216.1M | ||
| Q1 25 | $31.8M | $281.5M | ||
| Q4 24 | $-5.3M | $1.1B | ||
| Q3 24 | $26.6M | $316.2M | ||
| Q2 24 | $-2.1M | $218.9M | ||
| Q1 24 | $24.3M | $314.9M |
自由现金流EMBCESS
| Q4 25 | $16.6M | — | ||
| Q3 25 | $76.7M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $31.7M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-11.8M | — | ||
| Q1 24 | $20.9M | — |
自由现金流率EMBCESS
| Q4 25 | 6.4% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 27.3% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.3% | — | ||
| Q1 24 | 7.3% | — |
资本支出强度EMBCESS
| Q4 25 | 0.2% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 1.2% | — |
现金转化率EMBCESS
| Q4 25 | 0.39× | 12.53× | ||
| Q3 25 | 3.18× | 1.98× | ||
| Q2 25 | 1.78× | 0.93× | ||
| Q1 25 | 1.35× | 1.32× | ||
| Q4 24 | — | 3.54× | ||
| Q3 24 | 1.82× | 2.52× | ||
| Q2 24 | -0.14× | 2.21× | ||
| Q1 24 | 0.84× | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
ESS
暂无分部数据
